Literature DB >> 21544035

Current trends in living donor liver transplantation for primary sclerosing cholangitis.

David Seth Goldberg1, Benjamin French, Arwin Thomasson, K Rajender Reddy, Scott D Halpern.   

Abstract

BACKGROUND: Use of the Model for End-Stage Liver Disease (MELD) score has improved the efficiency of allocating deceased donor organs for liver transplant. However, its use may reduce access to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the MELD score variables. To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently.
METHODS: To test this hypothesis, we examined patients in the United Network for Organ Sharing database from December 1, 1994, to May 31, 2009.
RESULTS: In multivariable models conditioned on transplant center, patients with PSC were significantly more likely to receive a living donor transplant in both the pre-MELD (odds ratio [OR]=2.75; 95% confidence interval [CI], 2.20-3.44) and post-MELD eras (OR=4.08; 95% CI, 3.45-4.82). There was a significant interaction between PSC and post-MELD era of transplantation (OR=1.48; 95% CI, 1.11-1.97), indicating that patients with PSC were more likely to receive living donor transplants at baseline relative to patients without PSC, and that this effect was magnified following the introduction of the MELD score.
CONCLUSIONS: These findings raise the possibility that allocating livers on the basis of MELD score may have yielded the unintended consequence of increasing rates for living donor transplants for patients with PSC relative to patients with other forms of end-stage liver disease. Future research is needed to determine whether the practice of selectively transplanting patients with PSC with living donor transplants is associated with differences in clinical outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 21544035      PMCID: PMC3155574          DOI: 10.1097/TP.0b013e31821694b3

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database.

Authors:  Mark S Roberts; Derek C Angus; Cindy L Bryce; Zdenek Valenta; Lisa Weissfeld
Journal:  Liver Transpl       Date:  2004-07       Impact factor: 5.799

Review 2.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

3.  Primary sclerosing cholangitis: a long-term follow-up study.

Authors:  E Aadland; E Schrumpf; O Fausa; K Elgjo; A Heilo; T Aakhus; E Gjone
Journal:  Scand J Gastroenterol       Date:  1987-08       Impact factor: 2.423

4.  Factorial designs for randomized clinical trials.

Authors:  D P Byar; S Piantadosi
Journal:  Cancer Treat Rep       Date:  1985-10

5.  CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  E Björnsson; A Kilander; R Olsson
Journal:  Liver       Date:  1999-12

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

Authors:  Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

8.  Cholangiocarcinoma complicating primary sclerosing cholangitis.

Authors:  C B Rosen; D M Nagorney; R H Wiesner; R J Coffey; N F LaRusso
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

9.  Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Kelly Burak; Paul Angulo; Tousif M Pasha; Kathleen Egan; Jan Petz; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

10.  Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients.

Authors:  J H Helzberg; J M Petersen; J L Boyer
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

View more
  13 in total

1.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Liver Transplant in Patients With Primary Sclerosing Cholangitis.

Authors:  David S Goldberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

3.  Superior survival using living donors and donor-recipient matching using a novel living donor risk index.

Authors:  David S Goldberg; Benjamin French; Peter L Abt; Kim Olthoff; Abraham Shaked
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

Review 4.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

Review 5.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

6.  Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  David S Goldberg; Amanda Camp; Alvaro Martinez-Camacho; Lisa Forman; Brett Fortune; K Rajender Reddy
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

7.  Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Authors:  John E Eaton; Jayant A Talwalkar
Journal:  Curr Hepat Rep       Date:  2013-03-01

8.  Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.

Authors:  Fredric D Gordon; David S Goldberg; Nathan P Goodrich; Anna S F Lok; Elizabeth C Verna; Nazia Selzner; R Todd Stravitz; Robert M Merion
Journal:  Liver Transpl       Date:  2016-08-02       Impact factor: 5.799

9.  Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans.

Authors:  David S Goldberg; Benjamin French; Kimberly A Forde; Peter W Groeneveld; Therese Bittermann; Lisa Backus; Scott D Halpern; David E Kaplan
Journal:  JAMA       Date:  2014-03-26       Impact factor: 56.272

10.  Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes.

Authors:  Thomas G Cotter; Mohamad Minhem; Jennifer Wang; Thoetchai Peeraphatdit; Fares Ayoub; Anjana Pillai; Roberto Hernandez-Alejandro; Diego di Sabato; Michael Charlton
Journal:  Liver Transpl       Date:  2021-06-24       Impact factor: 6.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.